Skip to search formSkip to main contentSkip to account menu

BBI608

Known as: BB608, BBI-608 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Napabucasin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
760Background: The anti–programmed death 1 (PD-1) antibody, pembrolizumab provided an objective response rate (ORR) of 40% in… 
2017
2017
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic…
TPS3619Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and… 
2017
2017
Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
3529Background: Cancer stem cells are considered to be fundamentally important for resistance, recurrence and metastasis… 
2017
2017
CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
TPS4148Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and… 
2017
2017
Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC…
593Background: Cancer stem cells or stemness-high cancer cells are considered to be fundamentally important for resistance to… 
2017
2017
Abstract 4777: Cancer stemness and resistance: Napabucasin (BBI-608) sensitizes stemness-high cancer cells to Paclitaxel by inhibiting the STAT3-MUC1 pathway
Stemness-high cancer cells, or cancer stem cells (CSC) represent a subpopulation of cancer cells with enhanced tumorigenic… 
2016
2016
A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
9093Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor that works through inhibiting the… 
2015
2015
Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
4069 Background: BBI608, a first-in-class CSC inhibitor that works through inhibiting Stat3, has shown potent synergistic anti… 
2015
2015
A phase I study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer.
e15089 Background: BBI608 is an oral cancer stemness inhibitor which inhibits STAT3, β-catenin, and Nanog stemness pathways… 
2015
2015
A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti…
3617 Background: BBI608 is an oral first-in-class cancer stemness inhibitor that works by targeting Stat3. Potent preclinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)